Tirzepatide Telehealth

What Is Tirzepatide? The Dual GIP/GLP-1 Peptide Explained

The short version

Tirzepatide is a medicine that tells your body to handle sugar and fat more efficiently — the way your gut is supposed to do after a meal, but with a longer, stronger signal. Here is how it works in plain terms.

When you eat, your gut releases hormones called incretins. Two of them matter here: GIP and GLP-1. They signal the pancreas to release insulin only when blood sugar is actually high, and they also slow down how fast the stomach empties and reduce appetite. Tirzepatide is a synthetic 39-amino-acid peptide — a small protein chain — engineered to mimic both hormones at once. Because it activates both receptors, the dual signal is stronger than either alone.

It comes as a once-weekly subcutaneous injection (a small needle under the skin), with a half-life of roughly five days — long enough that one weekly dose keeps the signal going. The FDA approved it for type 2 diabetes in 2022, for obesity and weight management in 2023, and later for moderate-to-severe obstructive sleep apnea in adults with obesity. It is not approved for type 1 diabetes.

What is tirzepatide? Structure and classification

Tirzepatide is a synthetic incretin-mimetic peptide, also called a dual GIP and GLP-1 receptor agonist — the first of its class approved by the FDA. Its INN (international nonproprietary name) is tirzepatide; its development code was LY3298176.

The molecule is 39 amino acids long, built on the backbone of the native GIP sequence. A C20 fatty diacid moiety (eicosanedioic acid) — a lipid tail — is attached via a glutamic acid linker and two spacer units to a lysine side chain. That fatty-acid modification is structural: it binds albumin (a blood protein), slowing the molecule's clearance and giving it an approximately 5-day elimination half-life. Molecular formula: C225H348N48O68. Molecular weight: 4,813.53 Da. ATC code: A10BX16. CAS number: 2023788-19-2 [1][2].

The native GIP and GLP-1 hormones are secreted by different gut cell types in response to meals — GIP from K-cells in the upper small intestine, GLP-1 from L-cells further down. Both are incretins (gut hormones that stimulate insulin secretion in a glucose-dependent way). Tirzepatide mimics both with a single molecule [1].

The tirzepatide peptide is not a natural hormone and is not present in the body normally. It is manufactured synthetically.

Tirzepatide mechanism of action — how the dual signal works

Tirzepatide mechanism of action begins in the gut's incretin system. After a meal, GIP and GLP-1 are released into the bloodstream; they bind receptors on pancreatic beta cells and trigger insulin secretion — but only when blood glucose is already elevated (a safety feature called glucose-dependence). Tirzepatide engages both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) with a single molecule, amplifying this glucose-dependent insulin response more than either hormone alone [1].

In vitro signalling studies revealed two important properties. First, tirzepatide is an 'imbalanced' dual agonist — it engages the GIP receptor more fully than the GLP-1 receptor. Second, its GLP-1 receptor signalling is 'biased': it preferentially activates the cAMP-generating pathway over the beta-arrestin pathway (which typically leads to receptor internalisation and reduced response). Biased agonism at GLP-1R may prolong or enhance the insulin response compared with full, unbiased agonism [2].

Beyond insulin, the dual signal produces several downstream effects measured in trials: glucagon suppression (glucagon is the pancreatic hormone that raises blood sugar), delayed gastric emptying (slowing how fast the stomach passes food to the intestine), and reduced appetite and food intake through central nervous system pathways. Together these produce the compound's glycaemic and weight effects [1][10].

The delayed gastric emptying effect is transient — most studies show it attenuates with continued dosing — but it is also the mechanistic basis for some GI side effects and for the perioperative aspiration caution [15].

What is tirzepatide used for? Approved indications

As of 2025, tirzepatide carries three FDA-approved indications:

  1. Type 2 diabetes mellitus. Approved May 2022 as an adjunct to diet and exercise to improve glycaemic control in adults. The label confirms the dual GLP-1/GIP mechanism and the approved indication; weight-loss use was noted as off-label at the time of that approval [6][7].
  1. Chronic weight management. Approved November 2023 for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The approval was supported by the SURMOUNT trials [8].
  1. Moderate-to-severe obstructive sleep apnea in adults with obesity. Approved subsequently; supported by the SURMOUNT-OSA programme [11][12].

Beyond these three indications, trial programmes have investigated tirzepatide in heart failure with preserved ejection fraction (SUMMIT, 2025), metabolic dysfunction-associated steatohepatitis (SYNERGY-NASH, 2024), and kidney outcomes (SURPASS-CVOT pre-specified analysis, 2026). These are active research areas, not additional approved indications at the time of writing.

Tirzepatide is NOT approved for type 1 diabetes. It is not approved as a performance-enhancing agent and is a prescription-only medicine [7].

Is tirzepatide a GLP-1? Classification clarified

Tirzepatide is often placed in the GLP-1 receptor agonist class because it activates the GLP-1 receptor — the same receptor engaged by related approved agents. That classification is partly correct but incomplete. Tirzepatide is more precisely a dual GIP/GLP-1 receptor agonist: it is the first approved unimolecular agent that activates both the GIP receptor and the GLP-1 receptor [1].

The distinction matters for understanding both its greater efficacy and its specific safety profile. The GIP-receptor component adds to the metabolic benefit (the SURMOUNT trials produced larger weight reductions than those seen with selective GLP-1 receptor agonists in comparable trials) and may modify the GI adverse-effect pattern — one meta-analysis found tirzepatide increased cholelithiasis risk less than semaglutide in obesity trials, which some researchers attribute to differences in GIP-receptor engagement [13]. The full mechanistic account is on the research page.